Clinical Trials Logo
  1. Home
  2. CLN2 Disease
  3. NCT01907087

A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease

Batten Disease Clinical Trial

Official title:
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Clinical Trial Summary

The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease.

Clinical Trial Description

The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease. This is an open label Phase 1/2 study conducted in patients with CLN2 disease. Efficacy measures (disease rating scale and MRI) will be compared to a natural history control.

The study will be conducted under cGCP and patients will be closely monitored. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01907087
Study type Interventional
Source BioMarin Pharmaceutical
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 2013
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Recruiting NCT03307304 - Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
Active, not recruiting NCT03770572 - Gene Therapy for Children With CLN3 Batten Disease Phase 1/Phase 2
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Completed NCT00151268 - Genotype - Phenotype Correlations of LINCL N/A
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT01035424 - Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
Completed NCT00151216 - Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis Phase 1
Active, not recruiting NCT04273243 - Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
Recruiting NCT03285425 - Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Completed NCT02678689 - A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease Phase 2
Completed NCT02485899 - An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease Phase 1/Phase 2
Active, not recruiting NCT05174039 - An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease Phase 1/Phase 2
Terminated NCT01698229 - Collection of Cerebrospinal Fluid in Healthy Children N/A
Enrolling by invitation NCT03862274 - Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
Recruiting NCT01873924 - Clinical and Neuropsychological Investigations in Batten Disease
Completed NCT01161576 - Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) Phase 1
Recruiting NCT04613089 - Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database